Joseph M. Miller was named Chief Financial Officer of Lb Pharmaceuticals Inc, effective September 2, 2026. As of November 6, 2026, Lb Pharmaceuticals Inc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 10, 2026 to September 15, 2026, naming 1 appointment (Form 8-K, September 3, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Lb Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-15
- · In / out: In · Person: Joseph M. Miller · Role: Chief Financial Officer · Effective: 2026-09-02 · 8-K, 2026-09-03
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-10
Lb Pharmaceuticals Inc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-10 to 2026-09-15. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Lb Pharmaceuticals Inc files it.
Also on the record for Lb Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 13, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO. | 4.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by TCG Crossover GP II, LLC | 5% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.3% of the class | 5%+ stakes | Source |
| July 16, 2026 | Stake report, Schedule 13G, by JPMORGAN CHASE & CO | 5.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Caligan Partners LP | 5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 6.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by TCG Crossover GP II, LLC | 6.4% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO | 4.9% of the class | 5%+ stakes | Source |
| April 6, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 8.7% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13D/A, by Deep Track Capital, LP | 11.7% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lb Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Lb Pharmaceuticals Inc and the records around it.
Lb Pharmaceuticals Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Pontifax Management 4 G.P. (2015) Ltd. also filed stake reports on 3 other companies: Agomab Therapeutics NV (Apr 2026), Keros Therapeutics, Inc. (Oct 2025), Climb Bio, Inc. (Sep 2025)
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)
Watch Lb Pharmaceuticals Inc
Get an email when Lb Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lb Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lb Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lb Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 24 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-15 | Reported | not named in the filing | 8-K, 2026-09-15 | ||
| 2026-09-03 | In | Chief Financial Officer | 2026-09-02 | 8-K, 2026-09-03 | |
| 2026-06-10 | Reported | not named in the filing | 8-K, 2026-06-10 |
Who leads Lb Pharmaceuticals Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Joseph M. Miller, appointed, effective 2026-09-02 (filed 2026-09-03).
New leaders reset buying decisions — get the Full Report on Lb Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Lb Pharmaceuticals Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Lb Pharmaceuticals IncEvery change, in the filing's words
Reported
On September 15, 2026, LB Pharmaceuticals Inc (the "Company") announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company's Chief Medical Officer, effective as of September 14, 2026 (the "Start Date").
- Dr. Kozauer, age 54, served as the Senior Vice President, Head of Clinical Development at Centessa Pharmaceuticals from August 2025 to September 2026.
- Prior to that, she served as the Vice President in Clinical Development at Intra-Cellular Therapies, Inc. from November 2017 to August 2025 Earlier in her career.
- Dr. Kozauer held roles at Premier Research International LLC and Quintiles.
- Dr. Kozauer holds a BA from Cornell University and a medical degree from the George Washington University School of Medicine and Health Sciences, and she completed her residency in psychiatry at Georgetown University Medical Center.
- In connection with Dr. Kozauer's employment, the Company entered into an employment agreement (the "Employment Agreement"), which sets forth certain terms of Dr. Kozauer's employment.
- Pursuant to the Employment Agreement, Dr. Kozauer is entitled to an initial annual base salary of $515,000 (the "Annual Base Salary") and an annual discretionary bonus with a target amount equal to 40% of her annual base salary (the "Target Bonus").
- Dr. Kozauer is also entitled to a one-time cash sign-on bonus of $150,000 (the "Sign-on Bonus"), payable in a lump sum within 30 days following the Start Date.
Appointed: Joseph M. Miller, Chief Financial Officer, effective 2026-09-02
On September 3, 2026, LB Pharmaceuticals Inc (the "Company") announced that Joseph M. Miller has been appointed to serve as the Company's Chief Financial Officer, effective as of September 2, 2026 (the "Start Date").
- Mr. Miller, age 52, has over two decades of experience in both public and private biotech and commercial stage companies across the health sciences, biotech, and pharmaceutical sectors.
- Mr. Miller served as the Chief Financial Officer of Aurinia Pharmaceuticals Inc., a public biopharmaceutical company focused on delivering therapies to individuals with autoimmune diseases, from April 2020 to March 2026.
- Prior to that, Mr. Miller served as Chief Financial Officer, Principal Executive Officer, and Corporate Secretary at Avalo Therapeutics Inc. (formerly Cerecor, Inc.), a publicly traded biotech company.
- Before Cerecor, he was the Vice President of Finance at Sucampo Pharmaceuticals, Inc., where he was responsible for building out the finance organization to effectively support the company's rapid growth.
- Before Sucampo, Mr. Miller served in various progressive finance and management roles at QIAGEN N.V., and Eppendorf AG.
- He began his career in the audit practice of KPMG LLP.
- Mr. Miller earned his B.S. in accounting from Villanova University and is a Certified Public Accountant.
- In connection with Mr. Miller's employment, the Company entered into an employment agreement (the "Employment Agreement"), which sets forth certain terms of Mr. Miller's employment.
Reported
On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the " Separation Date ").
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
- On June 16, 2026, Anna Eramo, M.D., for personal reasons will transition to a role of advisor to LB Pharmaceuticals Inc (the "Company").
- She will continue to provide consulting services in a full-time capacity to the Company through September 15, 2026.
- Dr. Eramo's departure is not related to the Company's clinical program operations or practices, and the Company does not expect her departure to have a material impact on the Company's clinical development activities or previously disclosed clinical milestones.
- A search is underway for her replacement, and the Company has experienced clinical development and operations teams who will continue to oversee the execution of the ongoing clinical trials.
- In connection with her resignation, Dr. Eramo's has entered into a separation and consulting agreement with the Company, dated as of June 8, 2026 (the "Separation Agreement").
- Pursuant to the Separation Agreement, Dr. Eramo will provide consulting services to the Company for the three-month period following the Separation Date until September 15, 2026 (the "Consulting Period").
Tools for this story
Each opens in a new tab, filled in for Lb Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.